Drug-Susceptible Tuberculosis
American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of AmericaPublished: January 12, 2017
- Key Points
- Recommended Treatment Regimens
- Treatment in Special Situations
- Figures
- Factors to be considered in deciding to initiate treatment empirically for active tuberculosis
- Baseline And Follow-Up Evaluations For Patients Treated With First-Line Tuberculosis Medications
- Tables
- Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms
- Doses of Antituberculosis Drugs for Adults and Children
- Possible Components of a Multifaceted, Patient-Centered Treatment Strategy
- Examples of Priority Situations for the Use of Directly Observed Therapy
- Management of Treatment Interruptions
- Other Causes of Abnormal Liver Function Tests That Should Be Excluded
- Conditions or Situations in Which Therapeutic Drug Monitoring May Be Helpful
- Clinically Significant Drug–Drug Interactions Involving the Rifamycins
- Suggested Pyrazinamide Doses, Using Whole Tablets, for Adults Weighing 40–90 kg
- Suggested Ethambutol Dosages, Using Whole Tablets, for Adults Weighing 40–90 kg
- Dosing Recommendations for Adult Patients With Reduced Renal Function
Also Found In
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.